The Role of Aldosterone in Circulatory Disorders Within Type 2 Diabetes
NCT ID: NCT03017703
Last Updated: 2021-06-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
27 participants
INTERVENTIONAL
2016-12-01
2019-12-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Aldosterone and Vascular Disease in Diabetes Mellitus
NCT00214825
Aldosterone and Glucose Homeostasis
NCT00732160
Aldosterone Blockade in Chronic Kidney Disease: Influence on Arterial Stiffness and Kidney Function
NCT01100203
Aldosterone in Diabetic Nephropathy
NCT00870402
Increased Activity of a Renal Salt Transporter (ENaC) in Diabetic Kidney Disease
NCT01918488
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Type 2 Diabetes
8 weeks of treatment with Aldosterone blocker Eplerenone
Eplerenone
Healthy
8 weeks of treatment with Aldosterone blocker Eplerenone
Eplerenone
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Eplerenone
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI \< 32 kg/m2
* Non-smoking
* Blood pressure \< 140/90 mmHg (treatment with maximum of two antihypertensive drugs)
Exclusion Criteria
* Hypertension (\>140/90 mmHg)
* Sequelae to diabetes
* Smoking
* Known chronic diseases
* Pregnancy or birth within 3 month
* Alcohol misuse
40 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Southern Denmark
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Stefan Mortensen
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stefan P Mortensen, DMSc
Role: PRINCIPAL_INVESTIGATOR
University of Southern Denmark
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cardiovascular and Renal Research
Odense, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Finsen SH, Hansen MR, Hoffmann-Petersen J, Hojgaard HF, Mortensen SP. Eight weeks of mineralocorticoid blockade does not improve insulin sensitivity in type 2 diabetes. Physiol Rep. 2021 Aug;9(15):e14971. doi: 10.14814/phy2.14971.
Finsen SH, Hansen MR, Hansen PBL, Mortensen SP. Aldosterone Induces Vasoconstriction in Individuals with Type 2 Diabetes: Effect of Acute Antioxidant Administration. J Clin Endocrinol Metab. 2021 Mar 8;106(3):e1262-e1270. doi: 10.1210/clinem/dgaa867.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H- 15007940
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.